10-K Decoder · All companies

Tarsus Pharmaceuticals, Inc.

TARS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$451M$183M+147%
Operating income−$71.0M−$121M+41.1%
Net income−$66.4M−$116M+42.5%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026

$Q3 2026Year earlierChange
Revenue$195M$119M+63.9%
Operating income−$662M−$14.5M−4,466%
Net income−$668M−$12.6M−5,204%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Tarsus's revenue in FY2025?
$451M in FY2025 (Fiscal year ended Dec 31, 2025), +147% vs $183M a year earlier, per its 10-K filed Feb 2026.
Was Tarsus profitable in FY2025?
No: net income was −$66.4M and operating income −$71.0M in FY2025.
What was Tarsus's revenue in Q3 2026?
$195M (+63.9% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.